IP Library › Granted Patent US 9,827,299
Granted Patent B2
US 9,827,299 · App. 13/500,925 · Granted Nov 28, 2017

Selectively disrupted whole-cell vaccine

Inventors: Richard Malley (Beverly, MA); Porter Anderson (Key Largo, FL); Yingjie Lu (West Roxbury, MA); George A. Robertson (Fairfax Station, VA); Mark Alderson (Bainbridge Island, WA); Jean-Francois Lucien Maisonneuve (Federal Way, WA); Andrea Maria Tate (Issaquah, WA); Waldely de Oliveira Dias (Sao Paulo, BR); Viviane Maimoni Gonçalves (Sao Paulo, BR)
Assignees: Children's Medical Center Corporation; Path Vaccine Solutions; Fundacao Butantan
A61K39/092A61K2039/521A61K2039/543A61K2039/55505A61K2039/55544
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,827,299
App. No.
13/500,925
Granted
Nov 28, 2017
Kind
B2
Abstract

The present invention provides for immunogenic compositions and methods for producing an immunogenic composition with multiple immunity-inducing fractions of killed, whole-cell Streptococcus pneumoniae by selectively disrupting a whole cell bacterial preparation in such a manner that a soluble fraction that induces a primarily antibody response, and a cellular fraction that induces a primarily antibody-independent response, remain in the immunogenic composition.

Claims (7)

1. A method for producing a killed, whole-bacterial immunogenic composition from Streptococcus pneumoniae which elicits an antibody-mediated immune response and a T-lymphocyte mediated immune response, comprising

(i) selectively disrupting the Streptococcus pneumoniae bacteria in a bacterial preparation into a soluble fraction and an insoluble fraction using a solvent that is at least one of: an immiscible solvent, a volatile agent which evaporates at room temperature, or beta-propiolactone whereby the solvent maintains the overall structure of the Streptococcus pneumoniae bacterial cell,

(ii) removing the solvent by evaporation, hydrolysis or lyophilization or heat inactivation at 37° C. such that the soluble fraction is not removed from the bacterial preparation and both the soluble and cellular fraction remain in the immunogenic composition and wherein the bacterial cell preparation is not washed;

(iii) resuspending the bacterial preparation in an aqueous solution comprising an adjuvant, wherein the soluble fraction elicits an antibody-mediated immune response, and the cellular fraction elicits a T-lymphocyte mediated immune response.

2. The method according to claim 1 , wherein said soluble fraction induces a serotype-independent antibody response, and said cellular fraction induces increased phagocytosis.

3. The method according to claim 1 , wherein the immiscible solvent or volatile agent which evaporates at room temperature is chloroform or trichloroethylene.

4. The method according to claim 1 , wherein the adjuvant is Al(OH) 3 or aluminum phosphate.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2012
From: DE OLIVEIRA DIAS, WALDELY; MAIMONI GONCALVES, VIVIANE
To: FUNDACAO BUTANTAN
Reel/Frame 028231/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2012
From: ROBERTSON, GEORGE A.; ALDERSON, MARK; MAISONNEUVE, JEAN-FRANCOIS LUCIEN; TATE, ANDREA MARIA
To: PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH
Reel/Frame 028039/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2012
From: MALLEY, RICHARD; ANDERSON, PORTER; LU, YINGJIE
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 028039/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2012
From: PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH
To: PATH VACCINE SOLUTIONS
Reel/Frame 028039/0404 →
Continuity (3)
Provisional Application 61250348 · Oct 9, 2009
Provisional Application 61380429 · Sep 7, 2010
Related Publication 20120251577A1 · Oct 4, 2012